Literature DB >> 9600212

The extracellular matrix in multiple sclerosis lesions.

R A Sobel1.   

Abstract

Receptor-mediated recognition of extracellular matrix (ECM) molecules transduces intracellular signals that determine many cellular behaviors under normal and pathological conditions. This review briefly describes the major central nervous system (CNS) white matter ECM molecules and their receptors, the mechanisms by which the ECM may be altered in multiple sclerosis (MS) lesions, and potential roles for inflammatory and CNS resident cell interactions with specific ECM molecules in these lesions. In acute lesions, ECM recognition and cell signaling contribute to leukocyte migration through blood vessel walls, and within the CNS, through leukocyte and CNS resident cell immune activation and demyelination. An abnormal ECM in chronic MS lesions may preclude ECM-dependent developmental processes that lead to remyelination and axon regeneration. Thus, the composition of the ECM and the cellular recognition of its individual components may be critical to the pathogenesis of all stages of MS. An understanding of these complex interactions may lead to additional strategies for intervention and the promotion of reparative processes in MS patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9600212     DOI: 10.1097/00005072-199803000-00001

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  17 in total

1.  The oligodendrocyte precursor mitogen PDGF stimulates proliferation by activation of alpha(v)beta3 integrins.

Authors:  Wia Baron; Sanford J Shattil; Charles ffrench-Constant
Journal:  EMBO J       Date:  2002-04-15       Impact factor: 11.598

Review 2.  Polarity development in oligodendrocytes: sorting and trafficking of myelin components.

Authors:  Olaf Maier; Dick Hoekstra; Wia Baron
Journal:  J Mol Neurosci       Date:  2008-01-03       Impact factor: 3.444

3.  Inhibitors of myelination: ECM changes, CSPGs and PTPs.

Authors:  Danielle E Harlow; Wendy B Macklin
Journal:  Exp Neurol       Date:  2013-11-04       Impact factor: 5.330

4.  Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats.

Authors:  Giulia D'Intino; Michela Paradisi; Mercedes Fernandez; Alessandro Giuliani; Luigi Aloe; Luciana Giardino; Laura Calzà
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

Review 5.  Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire.

Authors:  Jens O Watzlawik; Bharath Wootla; Meghan M Painter; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Rev Neurother       Date:  2013-09       Impact factor: 4.618

Review 6.  Importance of oligodendrocyte protection, BBB breakdown and inflammation for remyelination.

Authors:  Jens Watzlawik; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Rev Neurother       Date:  2010-03       Impact factor: 4.618

7.  Thyroid hormone administration enhances remyelination in chronic demyelinating inflammatory disease.

Authors:  Mercedes Fernandez; Alessandro Giuliani; Stefania Pirondi; Giulia D'Intino; Luciana Giardino; Luigi Aloe; Rita Levi-Montalcini; Laura Calzà
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-08       Impact factor: 11.205

8.  Endothelial cell integrin laminin receptor expression in multiple sclerosis lesions.

Authors:  R A Sobel; J R Hinojoza; A Maeda; M Chen
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

9.  Promoting return of function in multiple sclerosis: An integrated approach.

Authors:  Mar Gacias; Patrizia Casaccia
Journal:  Mult Scler Relat Disord       Date:  2013-10-01       Impact factor: 4.339

Review 10.  Contributions of matrix metalloproteinases to neural plasticity, habituation, associative learning and drug addiction.

Authors:  John W Wright; Joseph W Harding
Journal:  Neural Plast       Date:  2010-02-10       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.